Basic Information
| RNALocate ID: | RLID:11000859 |
| RNA Symbol: | hsa-miR-26a-5p |
| Localization: | Microvesicle |
RNA Information
| RNA Name: | hsa-miR-26a-5p |
| RNA ID: | miRBase:MIMAT0000082 |
| RNA Category: | miRNA |
| Species: | Homo sapiens |
Localization Information
| PubMed ID: | 23077538 |
| Tissue/Cell Line: | Plasma |
| Method: | Solexa sequencing |
| Description: | To characterize the stability of secreted miRNAs in plasma, we selected eight plasma miRNAs with relatively high copy numbers detected by Solexa sequencing (Table S1).Data are collected from Table S1. |
Other Subcellular Localization
| RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
| RLID:01001347 | Cytoplasm | Nasopharyngeal carcinoma cells | 20498841 |
| RLID:01001348 | Cytoplasm | Neural progenitor cells | 21363885 |
| RLID:01001349 | Cytoplasm | Cell line (HeLa) | 21695135 |
| RLID:01001350 | Cytoplasm | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
| RLID:01001351 | Mitochondrion | Skeletal muscle myoblasts | 21637849 |
| RLID:01001352 | Mitochondrion | Cell line (HEK-293|HeLa) | 22984580 |
| RLID:01001353 | Nucleus | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
| RLID:01001354 | Nucleolus | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
| RLID:01001355 | Nucleus | Nasopharyngeal carcinoma cells | 20498841 |
| RLID:01001356 | Nucleus | Colon adenocarcinoma cells | 20864815 |
| RLID:11000849 | Exosome | Human cervical cancer cell line (HeLa) | 25760330 |
| RLID:11000850 | Exosome | Glioblastoma cells | 19011622 |
| RLID:11000851 | Exosome | Breast cancer cell line (MCF-7) | 20976003 |
| RLID:11000852 | Exosome | Primary dendritic cells|T cell line (J77) | 21505438 |
| RLID:11000853 | Exosome | Brain tissue | 23382797 |
| RLID:11000854 | Exosome | Plasma | 23663360 |
| RLID:11000855 | Exosome | Human mast cell line (HMC-1) | 24009880 |
| RLID:11000856 | Exosome | Breast cancer cell lines (MCF-7|MDA-MB-231) | 24468161 |
| RLID:11000857 | Exosome | Human esophageal cancer cell line (EC9706) | 25184951 |
| RLID:11000858 | Microvesicle | Glioblastoma cells | 19011622 |
| RLID:11000860 | Microvesicle | Seminal plasma | 23539611 |
| RLID-D:11000018 | Exosome | Blood|B lymphoblastoid cells|Breast milk|Chronic lymphocytic leukemia cells|Colon tissue|Endothelial cells|Epithelial cells|Lymphoma tissue|Mast cells|Seminal fluid|Tongue tissue | |
| RLID-D:11000281 | Microvesicle | Blood|Breast cell line|Colon cancer cell line (LIM1863)|Fibroblasts|Mesenchymal stem cells|Urine |
ncRNA Disease Information
| Resource | RNA Symbol | Disease | Link |
| MNDR | hsa-miR-26a-5p | Idiopathic pulmonary fibrosis | MNDR-E-MI-33070 |
| MNDR | hsa-miR-26a-5p | Diffuse large b cell lymphoma | MNDR-E-MI-33071 |
| MNDR | hsa-miR-26a-5p | Splenic marginal zone lymphoma | MNDR-E-MI-33072 |
| MNDR | hsa-miR-26a-5p | Multiple sclerosis chronic progressive | MNDR-E-MI-33073 |
| MNDR | hsa-miR-26a-5p | Oral squamous cell carcinoma | MNDR-E-MI-33074 |
| MNDR | hsa-miR-26a-5p | Large cell neuroendocrine cancer | MNDR-E-MI-33075 |
| MNDR | hsa-miR-26a-5p | Medulloblastoma | MNDR-E-MI-33076 |
| MNDR | hsa-miR-26a-5p | B cell lymphoma of malt type | MNDR-E-MI-33077 |
| MNDR | hsa-miR-26a-5p | Uterine corpus endometrial carcinoma | MNDR-E-MI-33078 |
| MNDR | hsa-miR-26a-5p | Lymphoma | MNDR-E-MI-33079 |
| MNDR | hsa-miR-26a-5p | Lymphoma non-hodgkin | MNDR-E-MI-33080 |
| MNDR | hsa-miR-26a-5p | Estrogen-receptor positive breast cancer | MNDR-E-MI-33081 |
| MNDR | hsa-miR-26a-5p | Estrogen-receptor negative breast cancer | MNDR-E-MI-33082 |
| MNDR | hsa-miR-26a-5p | Progesterone-receptor positive breast cancer | MNDR-E-MI-33083 |
| MNDR | hsa-miR-26a-5p | Progesterone-receptor negative breast cancer | MNDR-E-MI-33084 |
| MNDR | hsa-miR-26a-5p | Her2-receptor positive breast cancer | MNDR-E-MI-33085 |
| MNDR | hsa-miR-26a-5p | Niemann-pick disease type c | MNDR-E-MI-33086 |
| MNDR | hsa-miR-26a-5p | Precursor cell lymphoblastic leukemia-lymphoma | MNDR-E-MI-33087 |
| MNDR | hsa-miR-26a-5p | Anaplastic thyroid cancer | MNDR-E-MI-33088 |
| MNDR | hsa-miR-26a-5p | Dermatomyositis | MNDR-E-MI-33089 |
| MNDR | hsa-miR-26a-5p | Prostate cancer | MNDR-E-MI-33090 |
| MNDR | hsa-miR-26a-5p | Gastric cancer | MNDR-E-MI-33091 |
| MNDR | hsa-miR-26a-5p | Gastric lymphoma | MNDR-E-MI-33092 |
| MNDR | hsa-miR-26a-5p | Alzheimer disease | MNDR-E-MI-33093 |
| MNDR | hsa-miR-26a-5p | Intracranial aneurysm | MNDR-E-MI-33094 |
| MNDR | hsa-miR-26a-5p | Bladder cancer | MNDR-E-MI-33095 |
| MNDR | hsa-miR-26a-5p | Esophageal carcinoma | MNDR-E-MI-33096 |
| MNDR | hsa-miR-26a-5p | Dysautonomia familial | MNDR-E-MI-33097 |
| MNDR | hsa-miR-26a-5p | Myotonic dystrophy | MNDR-E-MI-33098 |
| MNDR | hsa-miR-26a-5p | Duchenne muscular dystrophy | MNDR-E-MI-33099 |
| MNDR | hsa-miR-26a-5p | Primary biliary cirrhosis | MNDR-E-MI-33100 |
| MNDR | hsa-miR-26a-5p | Graves disease | MNDR-E-MI-33101 |
| MNDR | hsa-miR-26a-5p | Leukemia | MNDR-E-MI-33102 |
| MNDR | hsa-miR-26a-5p | Cardiovascular disease | MNDR-E-MI-33103 |
| MNDR | hsa-miR-26a-5p | Carotid stenosis | MNDR-E-MI-33104 |
| MNDR | hsa-miR-26a-5p | Moyamoya disease | MNDR-E-MI-33105 |
| MNDR | hsa-miR-26a-5p | Lung cancer | MNDR-E-MI-33106 |
| MNDR | hsa-miR-26a-5p | Down syndrome | MNDR-E-MI-33107 |
| MNDR | hsa-miR-26a-5p | Parkinson disease | MNDR-E-MI-33108 |
| MNDR | hsa-miR-26a-5p | Niemann-pick disease | MNDR-E-MI-33109 |
| MNDR | hsa-miR-26a-5p | Breast cancer | MNDR-E-MI-33110 |
| MNDR | hsa-miR-26a-5p | Thyroid cancer | MNDR-E-MI-33111 |
| MNDR | hsa-miR-26a-5p | Pituitary neoplasms | MNDR-E-MI-33112 |
| MNDR | hsa-miR-26a-5p | Pancreatic cancer | MNDR-E-MI-33113 |
| MNDR | hsa-miR-26a-5p | Melanoma | MNDR-E-MI-33114 |
| MNDR | hsa-miR-26a-5p | Rectum adenocarcinoma | MNDR-E-MI-33115 |
| MNDR | hsa-miR-26a-5p | Epithelial ovarian cancer | MNDR-E-MI-33116 |
| MNDR | hsa-miR-26a-5p | Nephroblastoma | MNDR-E-MI-33117 |
| MNDR | hsa-miR-26a-5p | Colon cancer | MNDR-E-MI-33118 |
| MNDR | hsa-miR-26a-5p | Ischemic attack transient | MNDR-E-MI-33119 |
| MNDR | hsa-miR-26a-5p | Colon adenocarcinoma | MNDR-E-MI-33120 |
| MNDR | hsa-miR-26a-5p | West nile virus infection | MNDR-E-MI-33121 |
| MNDR | hsa-miR-26a-5p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-33122 |
| MNDR | hsa-miR-26a-5p | Familial ovarian cancer | MNDR-E-MI-33123 |
| MNDR | hsa-miR-26a-5p | Prostate adenocarcinoma | MNDR-E-MI-33124 |
| MNDR | hsa-miR-26a-5p | Kidney cancer | MNDR-E-MI-33125 |
| MNDR | hsa-miR-26a-5p | Thyroid adenomas | MNDR-E-MI-33126 |
| MNDR | hsa-miR-26a-5p | Glomerulonephritis | MNDR-E-MI-33127 |
| MNDR | hsa-miR-26a-5p | Carcinoma ductal breast | MNDR-E-MI-33128 |
| MNDR | hsa-miR-26a-5p | Glioblastoma | MNDR-E-MI-33129 |
| MNDR | hsa-miR-26a-5p | Glioblastoma multiforme somatic | MNDR-E-MI-33130 |
| MNDR | hsa-miR-26a-5p | Astrocytoma | MNDR-E-MI-33131 |
| MNDR | hsa-miR-26a-5p | Glioma | MNDR-E-MI-33132 |
| MNDR | hsa-miR-26a-5p | Chordoma | MNDR-E-MI-33133 |
| MNDR | hsa-miR-26a-5p | Amyotrophic lateral sclerosis | MNDR-E-MI-33134 |
| MNDR | hsa-miR-26a-5p | Osteosarcoma | MNDR-E-MI-33135 |
| MNDR | hsa-miR-26a-5p | Inclusion body myositis | MNDR-E-MI-33136 |
| MNDR | hsa-miR-26a-5p | Meningioma | MNDR-E-MI-33137 |
| MNDR | hsa-miR-26a-5p | Liver cancer | MNDR-E-MI-33138 |
| MNDR | hsa-miR-26a-5p | Uterus cancer | MNDR-E-MI-33139 |
| MNDR | hsa-miR-26a-5p | Gastric adenocarcinoma | MNDR-E-MI-33140 |
| MNDR | hsa-miR-26a-5p | Cervical squamous cell carcinoma | MNDR-E-MI-33141 |
| MNDR | hsa-miR-26a-5p | Pituitary adenoma | MNDR-E-MI-33142 |
| MNDR | hsa-miR-26a-5p | Lung squamous cell carcinoma | MNDR-E-MI-33143 |
| MNDR | hsa-miR-26a-5p | Lung adenocarcinoma | MNDR-E-MI-33144 |
| MNDR | hsa-miR-26a-5p | Thyroid carcinoma | MNDR-E-MI-33145 |
| MNDR | hsa-miR-26a-5p | Papillary thyroid carcinoma | MNDR-E-MI-33146 |
| MNDR | hsa-miR-26a-5p | Bladder urothelial carcinoma | MNDR-E-MI-33147 |
| MNDR | hsa-miR-26a-5p | Myasthenia gravis autoimmune experimental | MNDR-E-MI-33148 |
| MNDR | hsa-miR-26a-5p | Carcinoma renal cell | MNDR-E-MI-33149 |
| MNDR | hsa-miR-26a-5p | Kidney renal papillary cell carcinoma | MNDR-E-MI-33150 |
| MNDR | hsa-miR-26a-5p | Clear cell renal cell carcinoma | MNDR-E-MI-33151 |
| MNDR | hsa-miR-26a-5p | Biliary tract cancer | MNDR-E-MI-33152 |
| MNDR | hsa-miR-26a-5p | Cholangiocarcinoma | MNDR-E-MI-33153 |
| MNDR | hsa-miR-26a-5p | Esophageal cancer | MNDR-E-MI-33154 |
| MNDR | hsa-miR-26a-5p | Liver cirrhosis | MNDR-E-MI-33155 |
| MNDR | hsa-miR-26a-5p | Lung small cell carcinoma | MNDR-E-MI-33156 |
| MNDR | hsa-miR-26a-5p | Encephalopathy bovine spongiform | MNDR-E-MI-33157 |
| MNDR | hsa-miR-26a-5p | Head and neck squamous cell carcinoma | MNDR-E-MI-33158 |
| MNDR | hsa-miR-26a-5p | Myocardial infarction | MNDR-E-MI-33159 |
| MNDR | hsa-miR-26a-5p | Heart failure | MNDR-E-MI-33160 |
| MNDR | hsa-miR-26a-5p | Growth hormone-secreting pituitary adenoma | MNDR-E-MI-33161 |
| MNDR | hsa-miR-26a-5p | Breast invasive carcinoma | MNDR-E-MI-33162 |
| MNDR | hsa-miR-26a-5p | Hepatocellular carcinoma | MNDR-E-MI-33163 |
| MNDR | hsa-miR-26a-5p | Familiar ovarian carcinoma | MNDR-E-MI-33164 |
| MNDR | hsa-miR-26a-5p | B-cell lymphoma | MNDR-E-MI-33165 |
| MNDR | hsa-miR-26a-5p | Rheumatoid arthritis | MNDR-E-MI-33166 |
| MNDR | hsa-miR-26a-5p | T-cell leukemia | MNDR-E-MI-33167 |
| MNDR | hsa-miR-26a-5p | Retinoblastoma | MNDR-E-MI-33168 |
| MNDR | hsa-miR-26a-5p | Neuroblastoma | MNDR-E-MI-33169 |
| MNDR | hsa-miR-26a-5p | Barrett's adenocarcinoma | MNDR-E-MI-33170 |
| MNDR | hsa-miR-26a-5p | Osteoarthritis | MNDR-E-MI-33171 |
| MNDR | hsa-miR-26a-5p | Hodgkin lymphoma | MNDR-E-MI-33172 |
| MNDR | hsa-miR-26a-5p | Ulcerative colitis | MNDR-E-MI-33173 |
| MNDR | hsa-miR-26a-5p | Burkitt lymphoma | MNDR-E-MI-33174 |
| MNDR | hsa-miR-26a-5p | Tonsil cancer | MNDR-E-MI-33175 |
| MNDR | hsa-miR-26a-5p | Neuromyelitis optica | MNDR-E-MI-33176 |
| MNDR | hsa-miR-26a-5p | Skin cutaneous melanoma | MNDR-E-MI-33177 |
| MNDR | hsa-miR-26a-5p | Skin melanoma | MNDR-E-MI-33178 |
| MNDR | hsa-miR-26a-5p | Acute myelocytic leukemia | MNDR-E-MI-33179 |
| MNDR | hsa-miR-26a-5p | Colorectal cancer | MNDR-E-MI-33180 |
| MNDR | hsa-miR-26a-5p | Nasopharyngeal carcinoma | MNDR-E-MI-33181 |
| MNDR | hsa-miR-26a-5p | Nasopharynx carcinoma | MNDR-E-MI-33182 |
| MNDR | hsa-miR-26a-5p | Leukemia lymphoblastic acute | MNDR-E-MI-33183 |
| MNDR | hsa-miR-26a-5p | Ovarian epithelial cancer | MNDR-E-MI-33184 |
| MNDR | hsa-miR-26a-5p | Diabetic nephropathies | MNDR-E-MI-33185 |
| MNDR | hsa-miR-26a-5p | Ependymoma | MNDR-E-MI-33186 |
| MNDR | hsa-miR-26a-5p | Cardiac hypertrophy | MNDR-E-MI-33187 |
| MNDR | hsa-miR-26a-5p | Hyperalgesia | MNDR-E-MI-33188 |
| MNDR | hsa-miR-26a-5p | Nasopharyngeal cancer | MNDR-E-MI-33189 |
| MNDR | hsa-miR-26a-5p | Prostatic neoplasms | MNDR-E-MI-33190 |
| MNDR | hsa-miR-26a-5p | Sleep deprivation | MNDR-E-MI-33191 |
| MNDR | hsa-miR-26a-5p | Epstein-barr virus infections | MNDR-E-MI-33192 |
| MNDR | hsa-miR-26a-5p | Cerebral hemorrhage traumatic | MNDR-E-MI-33193 |
| MNDR | hsa-miR-26a-5p | Subarachnoid hemorrhage traumatic | MNDR-E-MI-33194 |
| MNDR | hsa-miR-26a-5p | Intracranial hemorrhage hypertensive | MNDR-E-MI-33195 |
| MNDR | hsa-miR-26a-5p | Chronic pain | MNDR-E-MI-33196 |
| MNDR | hsa-miR-26a-5p | Stroke lacunar | MNDR-E-MI-33197 |
| MNDR | hsa-miR-26a-5p | Non-alcoholic fatty liver disease | MNDR-E-MI-33198 |
| MNDR | hsa-miR-26a-5p | Barrett's carcinogenesis | MNDR-E-MI-33199 |
| MNDR | hsa-miR-26a-5p | Breast cancer her3+ negative | MNDR-E-MI-33200 |
| MNDR | hsa-miR-26a-5p | Duke C | MNDR-E-MI-33201 |
RNA Interaction Information
| Resource | RNA Symbol | Species | Link | RNALocate ID |
| RNAInter | ABCA1 | Homo sapiens | RR00022107 |
TOP